Correlation Between Esperion Therapeutics and ProQR Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and ProQR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and ProQR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Esperion Therapeutics and ProQR Therapeutics BV, you can compare the effects of market volatilities on Esperion Therapeutics and ProQR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of ProQR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and ProQR Therapeutics.

Diversification Opportunities for Esperion Therapeutics and ProQR Therapeutics

0.73
  Correlation Coefficient

Poor diversification

The 3 months correlation between Esperion and ProQR is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and ProQR Therapeutics BV in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ProQR Therapeutics and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with ProQR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ProQR Therapeutics has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and ProQR Therapeutics go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and ProQR Therapeutics

Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 0.92 times more return on investment than ProQR Therapeutics. However, Esperion Therapeutics is 1.09 times less risky than ProQR Therapeutics. It trades about -0.12 of its potential returns per unit of risk. ProQR Therapeutics BV is currently generating about -0.24 per unit of risk. If you would invest  215.00  in Esperion Therapeutics on December 29, 2024 and sell it today you would lose (54.00) from holding Esperion Therapeutics or give up 25.12% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Esperion Therapeutics  vs.  ProQR Therapeutics BV

 Performance 
       Timeline  
Esperion Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
ProQR Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days ProQR Therapeutics BV has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Esperion Therapeutics and ProQR Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Esperion Therapeutics and ProQR Therapeutics

The main advantage of trading using opposite Esperion Therapeutics and ProQR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, ProQR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will offset losses from the drop in ProQR Therapeutics' long position.
The idea behind Esperion Therapeutics and ProQR Therapeutics BV pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data